These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8959056)

  • 21. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis.
    Sato M; Chen CC; Akiyama K; Otsuki S
    Biol Psychiatry; 1983 Apr; 18(4):429-40. PubMed ID: 6860719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia.
    Sato M; Numachi Y; Hamamura T
    Schizophr Bull; 1992; 18(1):115-22. PubMed ID: 1553491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candidate gene networks and blood biomarkers of methamphetamine-associated psychosis: an integrative RNA-sequencing report.
    Breen MS; Uhlmann A; Nday CM; Glatt SJ; Mitt M; Metsalpu A; Stein DJ; Illing N
    Transl Psychiatry; 2016 May; 6(5):e802. PubMed ID: 27163203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders.
    McKetin R; Baker AL; Dawe S; Voce A; Lubman DI
    Psychiatry Res; 2017 May; 251():349-354. PubMed ID: 28282630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Changes in behavior and central monoaminergic systems in the rat after repeated methamphetamine pretreatment: presynaptic regulatory mechanism].
    Ichikawa J
    Yakubutsu Seishin Kodo; 1988 Sep; 8(3):389-403. PubMed ID: 3250152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Increasing prevalence of amphetamine--and methamphetamine-induced psychosis].
    Härtel-Petri R; Rodler R; Schmeisser U; Steinmann J; Wolfersdorf M
    Psychiatr Prax; 2005 Jan; 32(1):13-7. PubMed ID: 15633070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methamphetamine psychosis: epidemiology and management.
    Glasner-Edwards S; Mooney LJ
    CNS Drugs; 2014 Dec; 28(12):1115-26. PubMed ID: 25373627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report.
    Iwanami A; Sugiyama A; Kuroki N; Toda S; Kato N; Nakatani Y; Horita N; Kaneko T
    Acta Psychiatr Scand; 1994 Jun; 89(6):428-32. PubMed ID: 8085475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterizing prefrontal cortical activity during inhibition task in methamphetamine-associated psychosis versus schizophrenia: a multi-channel near-infrared spectroscopy study.
    Okada N; Takahashi K; Nishimura Y; Koike S; Ishii-Takahashi A; Sakakibara E; Satomura Y; Kinoshita A; Takizawa R; Kawasaki S; Nakakita M; Ohtani T; Okazaki Y; Kasai K
    Addict Biol; 2016 Mar; 21(2):489-503. PubMed ID: 25619621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-induced psychosis associated with crystalline methamphetamine.
    Dore G; Sweeting M
    Australas Psychiatry; 2006 Mar; 14(1):86-9. PubMed ID: 16630206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromechanism of developing methamphetamine psychosis: a neuroimaging study.
    Iyo M; Sekine Y; Mori N
    Ann N Y Acad Sci; 2004 Oct; 1025():288-95. PubMed ID: 15542729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users.
    Stuerenburg HJ; Petersen K; Bäumer T; Rosenkranz M; Buhmann C; Thomasius R
    Neuro Endocrinol Lett; 2002 Jun; 23(3):259-61. PubMed ID: 12080289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reaction time variability and related brain activity in methamphetamine psychosis.
    Fassbender C; Lesh TA; Ursu S; Salo R
    Biol Psychiatry; 2015 Mar; 77(5):465-74. PubMed ID: 25444164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methamphetamine-associated psychosis: Clinical presentation, biological basis, and treatment options.
    Chiang M; Lombardi D; Du J; Makrum U; Sitthichai R; Harrington A; Shukair N; Zhao M; Fan X
    Hum Psychopharmacol; 2019 Sep; 34(5):e2710. PubMed ID: 31441135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in Clinical Features of Methamphetamine Users with Persistent Psychosis and Patients with Schizophrenia.
    Wang LJ; Lin SK; Chen YC; Huang MC; Chen TT; Ree SC; Chen CK
    Psychopathology; 2016; 49(2):108-15. PubMed ID: 27071042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse childhood experiences and interaction with methamphetamine use frequency in the risk of methamphetamine-associated psychosis.
    Ding Y; Lin H; Zhou L; Yan H; He N
    Drug Alcohol Depend; 2014 Sep; 142():295-300. PubMed ID: 25064022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The clinical course of chronic methamphetamine psychoses].
    Fujimori H; Nakatani Y; Sakaguchi M
    Fortschr Neurol Psychiatr; 1989 Sep; 57(9):383-94. PubMed ID: 2793033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Six months follow-up of patients with methamphetamine psychosis.
    Yeh HS; Lee YC; Sun HJ; Wan SR
    Zhonghua Yi Xue Za Zhi (Taipei); 2001 Jul; 64(7):388-94. PubMed ID: 11584576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An exploratory analysis of neurocognition in methamphetamine-induced psychotic disorder and paranoid schizophrenia.
    Jacobs E; Fujii D; Schiffman J; Bello I
    Cogn Behav Neurol; 2008 Jun; 21(2):98-103. PubMed ID: 18541986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The relation between behavioral sensitization and glutamate release on the animal model of methamphetamine-induced psychosis].
    Honda M
    Hokkaido Igaku Zasshi; 2004 Jan; 79(1):65-78. PubMed ID: 14978976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.